Captopril Attenuates Cardiovascular and Renal Disease in a Rat Model of Heart Failure With Preserved Ejection Fraction.

摘要: Heart failure with preserved ejection fraction (HFpEF), a prevalent form of heart failure, is frequently accompanied by the metabolic syndrome and kidney disease. Because current treatment options HFpEF are limited, evaluation therapies in experimental models disease needed. In this study, we evaluated effects captopril, furosemide, their combination aged, obese ZSF1 rats, an animal model chronic as comorbidities. Captopril (100 mg/kg), furosemide (50 or was administered orally to rats aged 20 44 weeks. Untreated served controls. After 24 weeks treatment, captopril significantly lowered systemic blood pressure attenuated evidenced reduced left ventricular end diastolic pressures (10.5 ± 1.4 vs. 4.9 1.3 mm Hg Control Captopril, respectively) lower relaxation time constants (28.1 2.9 18.3 3.1 ms respectively). The captopril-induced improvement function associated cardiac hypertrophy, ischemia, necrosis, vasculitis. also increased renal flow glomerular filtration rate, vascular resistance proteinuria, improved histology (ie, glomerulosclerosis, tubular atrophy/dilation). Furosemide alone provided little benefit; moreover, did not augment therapeutic benefits captopril. This study suggests that administration but could be beneficial patients HFpEF, particularly those comorbidities such obesity, diabetes, dyslipidemias.